Myeloma U.K. Founder and former CEO Eric Low says there are still numerous obstacles stymieing access to innovative medicines, and that investments into removing those roadblocks have had little impact to date.
Low’s recent entry in pharmaphorum’s Deep Dive offers an in-depth look at market access in the current health care landscape, and some of the steps necessary to develop a “workable” and “sustainable” system.
“It’s hard to single out any one stakeholder group for specific blame,” Low writes. “The industry is, of course, always in the firing line. Rightly so, in some respects, but maybe not in others.”